Verastem, Inc.

VSTM

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001526119

B

second fifth of 370 graded peers in healthcare

rank 118 of 370; percentile 31.7; sampling error 2.5 points; lower is stronger

A B C D E

B, the elk



Scoreboard	
Profitability	A percentile 10.1
Solvency	D percentile 72.0
Growth and financing	C percentile 45.8
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $246.4M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution; fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 4, 2026 238 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	$10.10 2026-10-27; market equity $914.7M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 4, 2026

We are a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with challenging RAS/MAPK pathway-driven cancers. We market AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) in the United States ("U.S."), the first treatment specifically FDA-approved for adults with KRAS-mutated recurrent low-grade serous ovarian cancer ("LGSOC") who have received prior systemic therapy. AVMAPKI FAKZYNJA CO-PACK received accelerated approval in the U.S. on May 8, 2025.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 10.1						
Gross profitability	not computable	32.3%				
latest aligned inputs end 2018-12-31; latest annual assets end 2025-12-31						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Accruals ratio	(41.4%)	(6.6%)	10.1	805	2025-12-31	
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 1						
Solvency, sleeve percentile 72.0						
Twelve-month failure probability	0.18%	0.07%	67.3	246	2026-06-30	
Altman Z double-prime	(15.71)	(0.33)	70.7	751	2025-12-31	
Net debt to EBITDA	not computable	1.82x				
EBITDA must exceed $100,000						
Interest coverage	(149.50x)	(4.51x)	94.9	80	2025-12-31	
Current ratio	3.09x	2.94x	55.1	832	2025-12-31	
Growth and financing, sleeve percentile 45.8						
Revenue growth, three-year compound	not computable	10.1%				
four consecutive annual observations are required						
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 10						
Reinvestment rate	not computable	37.1%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	37.4%	2.1%	12.1	697	2025-12-31	
Net share issuance, one year	70.6%	2.5%	79.6	634	2026-02-27	

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 70.6%
Fortress balance sheet	cash minus debt is 48,094,000 USD; Altman Z is not used

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
113	Agios Pharmaceuticals, Inc. (AGIO)	30.4	B	short runway
114	BioNexus Gene Lab Corp. (BGLC)	30.6	B	dilution, late filer
115	Arcutis Biotherapeutics, Inc. (ARQT)	30.9	B	
116	Bio-Techne Corp. (TECH)	31.2	B	fortress balance sheet
117	Stryker Corp. (SYK)	31.4	B	
118	Verastem, Inc. (VSTM)	31.7	B	dilution, fortress balance sheet
119	Usana Health Sciences Inc. (USNA)	32.0	B	
120	Eton Pharmaceuticals, Inc. (ETON)	32.2	B	
121	CVRx, Inc. (CVRX)	32.5	B	
122	CorMedix Inc. (CRMD)	32.8	B	
123	Koru Medical Systems, Inc. (KRMD)	33.1	B	fortress balance sheet

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-10-27 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(18.2%)	7.7%	31
Distance from 52-week high	(5.1%)	(28.6%)	84
EBIT to enterprise value	(20.8%)	(1.5%)	23
Free cash flow yield	(11.5%)	(1.0%)	29
Book value to price	0.05	0.28	20
Sales to price	0.03	0.31	12
Composite equity issuance, five years	184.5%	20.5%	87
Relative strength against the sector, log excess return	(0.41)	(0.14)	31

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$136.4M
Operating cash flow, four quarters	-$162.2M
Months of runway	10.1
Days since last periodic filing	83 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	$17.3M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$26.7M	2018-12-31	2021-03-18	10-K	21-003211
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$165,000	2018-12-31	2019-03-12	10-K	19-001852
3	assets	us-gaap:Assets	$277.2M	2018-12-31	2020-03-11	10-K	20-002421
4	operating income	us-gaap:OperatingIncomeLoss	-$115.0M	2024-12-31	2026-03-04	10-K	26-023444
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$130.5M	2024-12-31	2026-03-04	10-K	26-023444
6	income tax	us-gaap:IncomeTaxExpenseBenefit	$185,000	2024-12-31	2026-03-04	10-K	26-023444
7	total debt	us-gaap:LongTermDebt	$40.7M	2024-12-31	2026-03-04	10-K	26-023444
8	book equity	us-gaap:StockholdersEquity	-$28.9M	2024-12-31	2026-03-04	10-K	26-023444
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$88.8M	2024-12-31	2026-03-04	10-K	26-023444
10	total debt	us-gaap:LongTermDebt	$40.1M	2023-12-31	2025-03-20	10-K	25-003372
11	book equity	us-gaap:StockholdersEquity	$57.4M	2023-12-31	2026-03-04	10-K	26-023444
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$77.9M	2023-12-31	2025-03-20	10-K	25-003372
13	net income	us-gaap:NetIncomeLoss	-$209.5M	2025-12-31	2026-03-04	10-K	26-023444
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$137.5M	2025-12-31	2026-03-04	10-K	26-023444
15	assets	us-gaap:Assets	$246.4M	2025-12-31	2026-03-04	10-K	26-023444
16	assets	us-gaap:Assets	$101.5M	2024-12-31	2026-03-04	10-K	26-023444
17	current assets	us-gaap:AssetsCurrent	$223.4M	2025-12-31	2026-03-04	10-K	26-023444
18	current liabilities	us-gaap:LiabilitiesCurrent	$72.3M	2025-12-31	2026-03-04	10-K	26-023444

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.2B	2025-12-31	2026-03-04	10-K	26-023444
20	operating income	us-gaap:OperatingIncomeLoss	-$170.1M	2025-12-31	2026-03-04	10-K	26-023444
21	book equity	us-gaap:StockholdersEquity	$57.2M	2025-12-31	2026-03-04	10-K	26-023444
22	liabilities	us-gaap:Liabilities	$189.2M	2025-12-31	2026-03-04	10-K	26-023444
23	depreciation amortization	us-gaap:Depreciation	$26,000	2024-12-31	2026-03-04	10-K	26-023444
24	interest expense	us-gaap:InterestExpense	$1.1M	2025-12-31	2026-03-04	10-K	26-023444
25	revenue	us-gaap:Revenues	$30.9M	2025-12-31	2026-03-04	10-K	26-023444
26	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$10.0M	2024-12-31	2025-03-20	10-K	25-003372
27	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.6M	2022-12-31	2025-03-20	10-K	25-003372
28	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.1M	2021-12-31	2023-03-14	10-K	23-003738
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$28,000	2024-12-31	2026-03-04	10-K	26-023444
30	current assets	us-gaap:AssetsCurrent	$95.0M	2024-12-31	2026-03-04	10-K	26-023444
31	current liabilities	us-gaap:LiabilitiesCurrent	$31.0M	2024-12-31	2026-03-04	10-K	26-023444
32	current assets	us-gaap:AssetsCurrent	$143.7M	2023-12-31	2025-03-20	10-K	25-003372
33	current liabilities	us-gaap:LiabilitiesCurrent	$26.4M	2023-12-31	2025-03-20	10-K	25-003372
34	assets	us-gaap:Assets	$149.7M	2023-12-31	2025-03-20	10-K	25-003372
35	assets	us-gaap:Assets	$95.0M	2022-12-31	2024-03-14	10-K	24-003250
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	87,835,106	2026-02-27	2026-03-04	10-K	26-023444
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	51,486,705	2025-03-19	2025-03-20	10-K	25-003372

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.